{"id":289303,"date":"2026-01-17T13:48:18","date_gmt":"2026-01-17T13:48:18","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/289303\/"},"modified":"2026-01-17T13:48:18","modified_gmt":"2026-01-17T13:48:18","slug":"how-low-can-boston-scientific-stock-go-when-markets-turn-sour","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/289303\/","title":{"rendered":"How Low Can Boston Scientific Stock Go When Markets Turn Sour?"},"content":{"rendered":"<p><img decoding=\"async\" class=\" top-image\" src=\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/01\/1768657698_355_0x0.jpg\" alt=\"The logo of Boston Scientific with the slogan &quot;Innovate for...\" data-height=\"2088\" data-width=\"3133\" fetchpriority=\"high\" style=\"position:absolute;top:0\"\/><\/p>\n<p>SHANGHAI, CHINA &#8211; 2025\/11\/08: The logo of Boston Scientific with the slogan &#8220;Innovate for Life&#8221; is shown at the 8th China International Import Expo. (Photo by Sheldon Cooper\/SOPA Images\/LightRocket via Getty Images)<\/p>\n<p>SOPA Images\/LightRocket via Getty Images<\/p>\n<p><a href=\"https:\/\/www.trefis.com\/data\/companies\/BSX?source=forbes&amp;from=BSX-2026-01-16\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BSX?source=forbes&amp;from=BSX-2026-01-16\" aria-label=\"Boston Scientific (BSX)\">Boston Scientific (BSX)<\/a> shares have decreased by 8.5% over the past 5 trading days. This recent drop highlights revived worries regarding the initial earnings dilution stemming from its Penumbra acquisition, yet such significant declines often raise a challenging question: is this weakness transitory, or does it indicate more profound issues within the company? As an aside, see <a class=\"color-link\" href=\"https:\/\/www.forbes.com\/sites\/greatspeculations\/2026\/01\/16\/3-catalysts-to-watch-out-for-google-stock\/\" data-ga-track=\"InternalLink:https:\/\/www.forbes.com\/sites\/greatspeculations\/2026\/01\/16\/3-catalysts-to-watch-out-for-google-stock\/\" target=\"_self\" aria-label=\"3 Catalysts To Watch Out For Google Stock.\" rel=\"nofollow noopener\">3 Catalysts To Watch Out For Google Stock.<\/a><\/p>\n<p>Before assessing its <strong>downturn resilience<\/strong>, let\u2019s examine Boston Scientific&#8217;s current position.<\/p>\n<ul>\n<li><strong>Size<\/strong>: Boston Scientific is a $133 billion company with $19 billion in revenue, currently trading at $90.03.<\/li>\n<li><a class=\"color-link\" href=\"https:\/\/www.trefis.com\/data\/companies\/BSX\/#financials\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BSX\/#financials\" aria-label=\"Fundamentals\"><strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BSX\/#financials\">Fundamentals<\/strong><\/a>: It has achieved a revenue growth of 21.6% over the last 12 months, along with an operating margin of 19.2%.<\/li>\n<li><strong>Liquidity<\/strong>: The company maintains a Debt to Equity ratio of 0.09 and a Cash to Assets ratio of 0.03.<\/li>\n<li><a class=\"color-link\" href=\"https:\/\/www.trefis.com\/data\/companies\/BSX\/#valuation_metrics_events\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BSX\/#valuation_metrics_events\" aria-label=\"Valuation\"><strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BSX\/#valuation_metrics_events\">Valuation<\/strong><\/a>: Boston Scientific&#8217;s stock is presently trading at a P\/E multiple of 47.8 and a P\/EBIT multiple of 37.0.<\/li>\n<li>Since 2010, there has been one instance where the stock dipped &gt;30% in &lt;30 days and later recovered by 41.1% within a year. Refer to <a href=\"https:\/\/www.trefis.com\/data\/companies\/BSX\/no-login-required\/ADPF2onf\/BSX-Dip-Buy-Analysis?source=forbes&amp;from=BSX-2026-01-16\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BSX\/no-login-required\/ADPF2onf\/BSX-Dip-Buy-Analysis?source=forbes&amp;from=BSX-2026-01-16\" aria-label=\"BSX Dip Buy Analysis\">BSX Dip Buy Analysis<\/a>.<\/li>\n<\/ul>\n<p>These indicators suggest <strong>Strong operational performance<\/strong>, coupled with a <strong>Very High<\/strong> valuation, rendering the stock <strong>Relatively Expensive<\/strong>. For further information, see <a href=\"https:\/\/www.trefis.com\/data\/companies\/BSX\/no-login-required\/rxlO4S4y\/Wait-For-A-Dip-To-Buy-Boston-Scientific-Stock?source=forbes&amp;from=BSX-2026-01-16\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BSX\/no-login-required\/rxlO4S4y\/Wait-For-A-Dip-To-Buy-Boston-Scientific-Stock?source=forbes&amp;from=BSX-2026-01-16\" aria-label=\"Buy or Sell BSX Stock\">Buy or Sell BSX Stock<\/a>.<\/p>\n<p>This leads us to a crucial consideration for investors concerned about this decline: how <strong>resilient<\/strong> is BSX stock if the market declines? This is where our <strong>downturn resilience<\/strong> framework becomes relevant. If BSX stock <strong>drops another 20-30%<\/strong> to $63, will investors be able to hold on comfortably? It turns out that the stock <strong>experienced a response slightly worse than<\/strong> the S&amp;P 500 index during various economic downturns, based on (a) how much the stock decreased and (b) how quickly it bounced back. Below, we delve deeper into each downturn.<\/p>\n<p>2022 Inflation Shock<\/p>\n<ul>\n<li>BSX stock fell 25.2% from a peak of $47.10 on 20 April 2022 to $35.24 on 14 June 2022, compared to a peak-to-trough decline of 25.4% in the S&amp;P 500.<\/li>\n<li>Nonetheless, the stock completely regained its pre-crisis peak by 12 December 2022.<\/li>\n<li>Since then, the stock has risen to a high of $108.14 on 8 September 2025 and is currently trading at $90.03.<\/li>\n<\/ul>\n<p>BSX Stock Performance During The 2022 Inflation Shock<\/p>\n<p>Trefis2020 Covid Pandemic<\/p>\n<ul>\n<li>BSX stock declined 43.5% from a high of $45.71 on 9 January 2020 to $25.83 on 23 March 2020, compared to a peak-to-trough decline of 33.9% in the S&amp;P 500.<\/li>\n<li>Nevertheless, the stock completely recovered to its pre-crisis peak by 2 August 2021.<\/li>\n<\/ul>\n<p>BSX Stock Performance During The 2020 COVID Pandemic<\/p>\n<p>Trefis2018 Correction<\/p>\n<ul>\n<li>BSX stock fell 18.7% from a peak of $39.04 on 2 October 2018 to $31.73 on 24 December 2018, compared to a peak-to-trough decline of 19.8% in the S&amp;P 500.<\/li>\n<li>Nevertheless, the stock fully recovered to its pre-crisis peak by 8 February 2019.<\/li>\n<\/ul>\n<p>BSX Stock Performance During The 2018 Correction<\/p>\n<p>Trefis2008 Global Financial Crisis<\/p>\n<ul>\n<li>BSX stock decreased by 70.5% from a peak of $18.59 on 30 January 2007 to $5.48 on 20 November 2008, compared to a peak-to-trough decline of 56.8% for the S&amp;P 500.<\/li>\n<li>However, the stock completely regained its pre-crisis peak by 2 November 2015.<\/li>\n<\/ul>\n<p>BSX Stock Performance During The 2008 Financial Crisis<\/p>\n<p>Trefis<\/p>\n<p>Feeling anxious about BSX stock? Consider a portfolio strategy.<\/p>\n<p>Portfolios Succeed When Individual Stocks Underperform<\/p>\n<p>Stock prices can fluctuate drastically &#8211; the essential aspect is remaining invested. A well-rounded portfolio keeps you in the market, enhances gains, and mitigates the risks associated with individual stocks.<\/p>\n<p>The Trefis <a href=\"https:\/\/www.trefis.com\/data\/companies\/PORTFOLIOS\/no-login-required\/RsQ6oXgC\/High-Quality-Portfolio-30-Stocks-with-210-Return-Since-2016-vs-94-for-S-P-500?source=forbes&amp;from=BSX-2026-01-16\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/PORTFOLIOS\/no-login-required\/RsQ6oXgC\/High-Quality-Portfolio-30-Stocks-with-210-Return-Since-2016-vs-94-for-S-P-500?source=forbes&amp;from=BSX-2026-01-16\" aria-label=\"High Quality (HQ) Portfolio\">High Quality (HQ) Portfolio<\/a>, featuring a selection of 30 stocks, has a consistent record of significantly outperforming its benchmark, which includes all three &#8211; the S&amp;P 500, S&amp;P mid-cap, and Russell 2000 indices. Why is this the case? As a collective, HQ Portfolio stocks have yielded superior returns with lower risk compared to the benchmark; providing a more stable investment experience, as evidenced by <a href=\"https:\/\/www.trefis.com\/data\/companies\/PORTFOLIOS\/no-login-required\/37ZjifdJ\/High-Quality-Portfolio-Fact-Sheet?source=forbes&amp;from=BSX-2026-01-16\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/PORTFOLIOS\/no-login-required\/37ZjifdJ\/High-Quality-Portfolio-Fact-Sheet?source=forbes&amp;from=BSX-2026-01-16\" aria-label=\"HQ Portfolio performance metrics\">HQ Portfolio performance metrics<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"SHANGHAI, CHINA &#8211; 2025\/11\/08: The logo of Boston Scientific with the slogan &#8220;Innovate for Life&#8221; is shown at&hellip;\n","protected":false},"author":2,"featured_media":289304,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[73],"tags":[21724,82826,144566,144567,79,18,19,17],"class_list":{"0":"post-289303","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business","8":"tag-boston-scientific","9":"tag-bsx","10":"tag-bsx-revenue","11":"tag-bsx-valuation","12":"tag-business","13":"tag-eire","14":"tag-ie","15":"tag-ireland"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115910758279551317","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/289303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=289303"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/289303\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/289304"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=289303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=289303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=289303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}